Healios KK Ord Shs HLOSF

Healthcare Biotechnology

Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.

PINL:HLOSF - Post by User

Healios KK Ord Shs

Bullboard Posts

Post by techrsvpon Feb 02, 2005 3:32pm

200 Views

Post# 8528494

conflict with wolfden

From what i read i think wolfden- halo require wriiten consent from campbell now metanor for the transfer of the option to halo,part of the regulatory due diligence still required and outstanding

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale